Rapamycin is an immunosuppressant for transplant patients, but it’s also been found to increase lifespan in lab animals. Dr. Alan Green, who prescribes rapamycin for anti-aging purposes, recommends Blagosklonny’s paper, Disease or not, aging is easily treatable:
Is aging a disease? It does not matter because aging is already treated using a combination of several clinically-available drugs, including rapamycin. Whether aging is a disease depends on arbitrary definitions of both disease and aging. For treatment purposes, aging is a deadly disease (or more generally, pre-disease), despite being a normal continuation of normal organismal growth. It must and, importantly, can be successfully treated, thereby delaying classic age-related diseases such as cancer, cardiovascular and metabolic diseases, and neurodegeneration.
[...]
As the simplest example, calorie restriction (CR) slows aging in diverse organisms, including primates [43-50]. Similarly, intermittent fasting (IF) and ketogenic diet (severe carbohydrate restriction) extend life span in mammals [48, 51-54]. CR (as well as carbohydrate restriction and IF fasting) improves health in humans [45, 48, 53, 55-62]. However, CR is unpleasant to most humans and its life-extending capacity is limited. Nutrients activate the mTOR (molecular Target of Rapamycin) nutrient-sensing pathway [63-65] and, as we will discuss mTOR drives aging, inhabitable by rapamycin. Rapamycin-based anti-aging therapies have been recently implemented by Dr. Alan Green (https://rapamycintherapy.com).
There’s a bit of circularity there.
“mTOR drives aging, inhabitable by rapamycin.”
He probably meant to say “inhibitable”.